Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Blinatumomab (Blincyto) was effective in inducing a complete remission in 33% of patients with relapsed or refractory Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL). Grade 3 or 4 adverse effects occur frequently.
D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy*
D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab